Are there any upcoming catalysts, such as conference presentations or data readouts, that could move the stock price?

Yes – the company has a clear, near‑term catalyst that could move the stock.

How this catalyst could affect the stock

1. Positive financial results or a stronger‑than‑expected cash‑position – May lift the share price as the market perceives reduced near‑term risk.
   
2. Encouraging clinical‑data updates on zorevunersen – Even a modest data‑readout (e.g., interim safety or efficacy signals) can generate a sizable upside for a company whose valuation is heavily tied to its lead program.
   
3. New partnership or licensing announcements – If management signals a collaboration with a larger pharma partner, the market typically reacts positively.
   
4. Guidance revisions – Raising or lowering Q3/Q4 guidance on revenue, R&D spend, or timeline for key milestones will immediately be reflected in price action.

What to watch for during the call

• Updates on the Dravet‑syndrome program (zorevunersen) – Any mention of upcoming Phase 2/3 enrollment, interim analyses, or regulatory interactions.
  
• Cash‑runway and financing plans – Whether the company will need to raise additional capital (dilutive) or has secured non‑dilutive funding.
  
• Potential conference presentations – While not listed in the press release, management often hints at upcoming abstract submissions or presentations at major neurology or genetics meetings (e.g., American Epilepsy Society (AES) meeting, Neuroscience 2025, BIO conference). If such presentations are slated, they become secondary catalysts.
  
• Milestone timelines – Any new target dates for IND filings, data readouts, or regulatory meetings.

Bottom line

• Primary catalyst: The August 12, 2025 webcast/analyst call is the immediate event that can move Stoke Therapeutics’ stock, as it will deliver Q2 2025 financial results and likely provide the first public update on the zorevunersen program’s progress.
  
• Secondary catalysts: While not explicitly mentioned in the news release, management may preview upcoming conference abstracts or data‑readout timelines (e.g., interim safety/efficacy data) that could act as additional price drivers later in the year.

Investors should therefore monitor the August 12 call closely for any clinical‑data updates, financial guidance changes, or partnership announcements—all of which are the key levers that historically shift the valuation of early‑stage RNA‑medicine biotech companies like Stoke Therapeutics.